期刊
AMERICAN JOURNAL OF HUMAN GENETICS
卷 108, 期 9, 页码 1735-1751出版社
CELL PRESS
DOI: 10.1016/j.ajhg.2021.07.001
关键词
-
资金
- National Institute of General Medical Sciences of the National Institutes of Health [R24GM115277, R01GM132162]
- National Human Genome Research Institute of the NIH [T32 HG00035]
- National Institute of General Medical Sciences of the NIH [P01GM11669]
- Howard Hughes Medical Institute
The CYP2C9 gene encodes an enzyme that plays a crucial role in metabolizing small molecule drugs, and its variants can impact drug response and increase the risk of bleeding. By utilizing the clickseq and VAMP-seq technologies, researchers measured the activity and cellular abundance of numerous CYP2C9 variants, revealing a significant portion with decreased activity and functional differences attributed to changes in protein abundance.
CYP2C9 encodes a cytochrome P450 enzyme responsible for metabolizing up to 15% of small molecule drugs, and CYP2C9 variants can alter the safety and efficacy of these therapeutics. In particular, the anti-coagulant warfarin is prescribed to over 15 million people annually and polymorphisms in CYP2C9 can affect individual drug response and lead to an increased risk of hemorrhage. We developed clickseq, a pooled yeast-based activity assay, to test thousands of variants. Using click-seq, we measured the activity of 6,142 missense variants in yeast. We also measured the steady-state cellular abundance of 6,370 missense variants in a human cell line by using variant abundance by massively parallel sequencing (VAMP-seq). These data revealed that almost two-thirds of CYP2C9 variants showed decreased activity and that protein abundance accounted for half of the variation in CYP2C9 function. We also measured activity scores for 319 previously unannotated human variants, many of which may have clinical relevance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据